Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04818593
Other study ID # 21-00021
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 18, 2021
Est. completion date November 29, 2021

Study information

Verified date June 2023
Source NYU Langone Health
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate whether the percentage of good quality embryo formation following Intracytoplasmic Sperm Injection (ICSI) is improved with the use of ZyMot method of microfluidic sperm separation compared to density gradient.


Description:

During an in vitro fertilization (IVF) cycle, eggs are removed from a woman's ovaries via a minor surgical procedure and are inseminated with sperm in order to create embryos. The insemination process can be via standard IVF or intracytoplasmic sperm injection (ICSI.) Standard IVF is the process of placing thousands of sperm in a culture dish with one or more eggs and allowing them to interact on their own. ICSI is the process by which one sperm is directly injected into each egg. Prior to using the sperm for insemination, a semen sample is processed and washed in order to obtain the healthiest sperm. A standard sperm preparation procedure is density gradient, in which the sperm is spun via centrifugation and separated from the seminal fluid. An alternate method is via microfluidics, by which the sperm swim up a microfluidic gradient created by a microporous filter between two chambers of a device. Sperm that are capable of navigating through this filter and reaching the end chamber are presumed to be the healthiest sperm. There is some data revealing that ZyMot microfluidics yields healthier sperm compared to the density gradient technique. The aim of the study is to evaluate whether good quality embryo formation is any different following insemination with sperm separated by microfluidics compared to density gradient. On the day of oocyte retrieval, the sperm sample will be split between the two different processing methods: density gradient and ZyMot microfluidics. In the event that there are 6 or more mature oocytes and ICSI will be used for insemination, half of the oocytes will be inseminated with sperm processed by density gradient and half with sperm processed by ZyMot microfluidics. The percentage of good quality embryo formation will be compared between the two groups.


Recruitment information / eligibility

Status Completed
Enrollment 108
Est. completion date November 29, 2021
Est. primary completion date November 29, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria for Patients: 1. Patient(s) over 18 years of age 2. Patient(s) capable of providing informed consent 3. Use or possible use of ICSI for oocyte insemination 4. At least 6 mature oocytes at time of insemination via ICSI Exclusion Criteria for Patients: 1. Patient under 18 y/o 2. Patients not capable of providing informed consent 3. Use of IVF for insemination 4. Less than 6 mature oocytes at time of rertrieval 5. Anonymous donor sperm source 6. Surgically retrieved sperm 7. Sperm sample not sufficient for use with ZyMot device Inclusion Criteria for Donors: 1. Donor(s) over 18 years of age 2. Donor(s) capable of providing informed consent 3. Use of ejaculate sperm, fresh or frozen, for insemination 4. Sufficient sperm for use of ZyMot Exclusion Criteria for Donors: 1. Anonymous donors

Study Design


Related Conditions & MeSH terms


Intervention

Device:
ZyMot Multi Sperm Separation Device (850 ul)
850 uL of untreated semen will be directly deposited into the inlet port of the ZyMotTM Multi device, followed by placement of 750 uL culture medium in the outlet port and throughout the upper collection chamber. The device will then be incubated in a humidified 37C CO2 incubator for 30 minutes. During incubation, the healthiest and most motile sperm will swim through the microporous filter and into the upper collection chamber, where they will be recovered via the outlet port. 500 uL of the sperm sample will be removed and placed in a separate tube for analysis and insemination.
Other:
Density Gradient Centrifugation
Density gradient centrifugation will be performed using a one-layer preparation of 90% Isolate in 15 mL conical tubes. Semen will be layered over 1 mL of gradient and then centrifuged for 15 min at 300xg. The supernatant will be removed and discarded. The sperm pellet will be washed by mixing with Multipurpose Handling Medium Complete and centrifuging the sample for 5 min at 400xg. After the wash, the supernatant is removed and discarded and the pellet is re-suspended in culture medium, assessed for sperm parameters, and held at room temperature until insemination.

Locations

Country Name City State
United States NYU Langone Reproductive Specialists of NY New York New York

Sponsors (1)

Lead Sponsor Collaborator
NYU Langone Health

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Good Quality Blastocyst Formation Good quality embryos will be defined as blastocyst stage embryos on day 5 or 6 of culture with an overall quality grade of good or fair. Embryo morphology assessment includes two parts: an Overall Grade and the Stage. Grading is a subjective assessment of the overall quality of the embryo as good, fair, or poor, and is based on assessment of certain characteristics of the embryo, such as fragmentation, symmetry, inner cell mass (ICM) quality and trophectoderm quality. The percentage will be reported for both arms (ZyMot compared to density gradient). Culture Day 5 or 6
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06044792 - The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
Completed NCT04039217 - Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM Phase 4
Active, not recruiting NCT04588883 - Strengthening Families Living With HIV in Kenya N/A
Not yet recruiting NCT03120884 - Intracytoplasmic Sperm Injection in Non-male Factor Infertility in Advanced Maternal Age N/A
Recruiting NCT03421314 - Effect of Zinc and Selenium Supplementation on HIV+ Individuals on Antiretroviral Treatment. N/A
Completed NCT04546412 - Importance of the Microtubule Cytoskeleton in Oocyte Competence
Completed NCT03343938 - Evaluation of a Closed Assisted Reproductive Technology (ART) Station Versus an Open Flow Cabinet N/A
Completed NCT03808194 - Lotto to Link Study: A Prospective, Interventional, Randomized Study of Conditional Incentives N/A
Active, not recruiting NCT04910711 - Investigating the Interaction Between Two Long-acting Reversible Methods of Contraception and Dolutegravir, a Treatment for HIV Phase 4
Completed NCT04714255 - Efficacy of Art Intervention on Decreasing Pain and Anxiety During Intravenous Cannulation N/A
Recruiting NCT03804294 - Effect of Vitamin D on Outcome of Assisted Reproductive Technology(ART);
Recruiting NCT05090150 - The SMART ART Study N/A
Recruiting NCT05075174 - Effect of Progesterone Levels on 15th Day After Embryo Transfer in Early Miscarriage < 7 WG or Evolving Pregancy Rates
Recruiting NCT05358678 - Cesarean Section Scar Niche: The Impact on ART Outcome
Completed NCT02929992 - Delivery Optimization for Antiretroviral Therapy (The DO ART Study) N/A
Recruiting NCT05528536 - Acceptance and Commitment Therapy and Exercise for Older Adults With Chronic Pain N/A
Completed NCT04396210 - Patients Perspectives on Discontinuation of Their Fertility Treatment Due to the COVID-19 Pandemic
Completed NCT05053178 - The Effect of Mindfulness-Based Mandala Activity on Anxiety and Spiritual Well-Being Levels of Senior Nursing Students N/A
Not yet recruiting NCT06334003 - Cardiometabolic Function in Offspring, Mother and Placenta After Assisted Reproductive Technology
Recruiting NCT05962775 - Ethanol Sclerotherapy Prior to ART N/A